Please do explain your thinking here. SAVA starts recruiting at the earliest in Oct/2021 on a Phase 3 trial that runs for one year after the last patient is enrolled....so lets say TLD on the PH3-Alz is in Q3-Q4 2023. Anavex fully enrolled and almost all patients enrolled in extension. Data due out 2H 2022.
IMO I wouldn't touch SAVA with a 10' pole. With a $4b market cap, it still has much room to fall. Sharks are in the water for sure, and the company, regardless if they are guilty of allegations, will be mired in legal battles that will consume much time, energy and funds.